Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about DaVita Inc.
DaVita Inc. News
DaVita Inc. Quantitative Score
About DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
DaVita Inc. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
DaVita Inc. Financials
Table Compare
Compare DVA metrics with: | |||
|---|---|---|---|
Earnings & Growth | DVA | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | DVA | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | DVA | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | DVA | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
DaVita Inc. Income
DaVita Inc. Balance Sheet
DaVita Inc. Cash Flow
DaVita Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Sell |
| Return on Assets | Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
DaVita Inc. Executives
| Name | Role |
|---|---|
| Mr. Javier J. Rodriguez | Chief Executive Officer & Executive Director |
| Mr. Joel Ackerman | Chief Financial Officer & Treasurer |
| Ms. Kathleen Alyce Waters | Chief Legal & Public Affairs Officer |
| Mr. David P. Maughan | Chief Operating Officer of Kidney Care |
| Mr. James O. Hearty | Chief Compliance Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Javier J. Rodriguez | Chief Executive Officer & Executive Director | Male | 1971 | 5.96M |
| Mr. Joel Ackerman | Chief Financial Officer & Treasurer | Male | 1965 | 2.24M |
| Ms. Kathleen Alyce Waters | Chief Legal & Public Affairs Officer | Female | 1968 | 2.02M |
| Mr. David P. Maughan | Chief Operating Officer of Kidney Care | Male | 1977 | 1.93M |
| Mr. James O. Hearty | Chief Compliance Officer | Male | 1969 | 1.4M |
DaVita Inc. Insider Trades
| Date | 15 Aug |
| Name | Schechter Adam H |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 369 |
| Date | 15 Aug |
| Name | YALE PHYLLIS R |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 369 |
| Date | 15 Aug |
| Name | DESOER BARBARA J |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 369 |
| Date | 15 Aug |
| Name | Hollar Jason M. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 369 |
| Date | 15 Aug |
| Name | Moore Gregory J. |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 369 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 15 Aug | Schechter Adam H | Director | Acquired | A-Award | 369 |
| 15 Aug | YALE PHYLLIS R | Director | Acquired | A-Award | 369 |
| 15 Aug | DESOER BARBARA J | Director | Acquired | A-Award | 369 |
| 15 Aug | Hollar Jason M. | Director | Acquired | A-Award | 369 |
| 15 Aug | Moore Gregory J. | Director | Acquired | A-Award | 369 |